
AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing...

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments....

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...

Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...